PHARMA TECH

Aidoc and Subtle Medical Partner to Bring End-to-End AI Solutions to Medical Imaging

Aidoc | September 15, 2021

Aidoc and Subtle Medical Partner to Bring End-to-End AI Solutions to Medical Imaging
Aidoc, leading provider of AI for medical imaging, announced today a partnership with Subtle Medical, developer of leading AI-based image enhancement bringing best-of-breed AI to both image acquisition and post-acquisition clinical workflows. Aidoc has developed the industry's most robust AI platform, delivering a unified and seamless cross-specialty AI experience for physicians in over 500 medical centers, including the largest clinical deployment of AI in healthcare at Radiology Partners.

"Mainstream healthcare adoption of AI requires both a comprehensive package of premier AI solutions and an ability to deliver their results in a reliable and seamless manner across physician workflow, Through this partnership, we will provide health systems and imaging centers with Subtle Medical's optimal solution, now seamlessly delivered through a unified AI architecture. Our platform's ability to deliver interoperable AI solutions is a game changer for AI adoption."

- Tom Valent, VP of Business Development at Aidoc.

A pioneer in healthcare AI, Aidoc's FDA-cleared solutions analyze medical images for critical conditions and trigger actionable alerts directly in the imaging workflow supporting medical specialists in reducing turnaround time and improving quality of care.  Subtle Medical's AI-powered software solutions, SubtlePET™ and SubtleMR™ are image enhancement tools that increase the efficiency of image capture by improving the quality of accelerated scans. This enables optimized scan times and can potentially increase the number of patients scanned per day. Subtle's solutions are compatible with all scanner brands, models and field strengths so institutions can see the benefit across their entire scanner fleet.

"This agreement will provide our customers with a multimodality solution that includes acquisition workflow efficiencies and image quality improvements together with Aidoc's post-acquisition clinical workflow solutions, We believe that the integration of Subtle's AI-based software tools with the Aidoc platform will dramatically change the medical imaging equation."

- Josh Gurewitz, Chief Commercial Officer at Subtle Medical. 


About Subtle Medical
Subtle Medical, Inc. is a leading healthcare technology company making medical imaging faster, safer, and smarter. For more information, visit subtlemedical.com.

About Aidoc
Aidoc is the leading provider of artificial intelligence solutions that support and enhance the impact of physician diagnostic power - helping them expedite patient treatment and improve quality of care.

Spotlight

The lives of pharmacists and the medicines they manage have changed dramatically since the NHS was created. Here, we chart the milestones that shaped the profession.

Related News

POLICY AND REGULATION

EpiEndo Pharmaceuticals Secures Funding to Advance Clinical Development of its Non-Antibiotic Macrolide for the treatment of COPD

EpiEndo Pharmaceuticals | August 19, 2021

EpiEndo Pharmaceuticals , a privately held biopharmaceutical company focused on a novel barrier enhancing approach to the treatment of chronic inflammatory airway diseases such as chronic obstructive pulmonary disease (COPD), announces the closing of a €20m Series A financing round led by Flerie Invest and Iðunn Venture Fund, with existing investors ABC Ventures participating, along with the European Innovation Council (EIC) Fund joining the round. The financing secures funds to advance clinical development of EpiEndo’s lead compound EP395, which entered phase I clinical trials in April, through Phase IIa, targeting COPD as a primary indication. EpiEndo’s development rationale is based on a newly acknowledged therapeutic paradigm, that loss of integrity of epithelial barriers plays a critical role in propagating chronic inflammatory diseases in lungs and contributes to vulnerability to infections associated with acute exacerbations of airway diseases. “I am delighted to announce the closing of this new investment round,” commented Maria Bech, CEO of EpiEndo Pharma. “We are very pleased to welcome such well-reputed investors as Flerie Invest and Iðunn Venture Fund to help us build our company and are honoured that the European Innovation Council Fund has chosen EpiEndo as its first follow-on investment. We are also grateful for the continued support of our existing investors. This financing is a major step for EpiEndo, not only funding our lead compound through clinical development in patients with COPD, but also enabling exploration of other important potential therapeutic application areas such as dermatology and gastrointestinal disorders, where compromised epithelial integrity is known to contribute to disease pathophysiology.” Macrolide antibiotics such as azithromycin have been known for decades to exhibit good disease modifying efficacy against many chronic inflammatory airway diseases in addition to their antibacterial properties, in which their long-term use reduces the frequency and severity of inflammatory flare-ups and exacerbations. Although beneficial for overall health and prognosis, their off-label use in these patient populations has led to the emergence of macrolide resistance in the host flora. EpiEndo’s lead compound EP395 is a new chemical entity in which the epithelial regenerative properties and anti-inflammatory effects seen with macrolides have been augmented, and the anti-bacterial properties removed. Using this Series, A funding, EpiEndo aims to advance the clinical development of EP395 towards approval as the first disease modifying non-antibiotic macrolide that can be prescribed safely and effectively as a long-term treatment for patients with COPD. “We have followed EpiEndo for some time and have seen impressive progress towards clinical phase of their lead compound EP 395. We are proud to take part in their continuing journey with the aim to deliver substantially improved treatment of COPD,” said Carl-Johan Spak, Senior Advisor at Flerie Invest. “EpiEndo is an attractive investment opportunity for Iðunn and a good fit for our fund’s investment strategy. We are looking forward to work with the company in the coming years to develop its lead candidate through the coming clinical phases. It is important for Iðunn to participate in the translation of new scientific discovery into clinical practice,” commented Hilmar Bragi Janusson, Managing Director of Iðunn Venture Fund. “ABC is thrilled to obtain, in this round, a group of new investors to co-lead with us and support EpiEndo´s quest to create a solution to some of the most problematic diseases,” commented Ivar Gudjonsson, Managing Director of ABC Venture and a board member of EpiEndo. “EpiEndo Pharmaceuticals’ challenge is to develop a new class of drugs and we are delighted to take part in this scale up journey,” said José Fernando Figueiredo, EIC Fund Investment Committee member, “The EIC Fund is taking part in this financial round to help this great example of a life science company to develop and deploy breakthrough treatment of chronic obstructive inflammatory pulmonary disease.” About EpiEndo Pharmaceuticals EpiEndo is a clinical-stage biopharmaceutical company with a unique approach to inflammatory disorders that focuses on enhancement of epithelial barrier integrity as a critical pathophysiological factor underlying the etiology of a number of major diseases. Epithelial cells are a key component of the barrier that makes up human lung tissue and other organs such as the gut and skin. Compromised integrity of this barrier is implicated in the progression and non-resolution of several chronic inflammatory diseases. EpiEndo is developing a proprietary portfolio of orally available macrolide drugs with promise as first-in-class disease-modifying therapeutics, to address the huge global burden of chronic diseases of the lung and other organs where there is other significant unmet medical need. EpiEndo’s lead drug candidate, EP395, aims to be the first on-market oral, non-antibiotic, barrier strengthening and anti-inflammatory macrolide for the treatment of COPD.

Read More

Red River Biorefinery Now Producing Pharmaceutical Grade (USP) Ethanol for Hand Sanitizers and Disinfectants

Red River Biorefinery | October 06, 2020

The Red River Biorefinery (RRB) announced today that it has expanded production to supply ethanol that meets the U.S. Pharmacopeia (USP) purity and quality standards to the hand sanitizer market. To help meet the increase in global demand for hand sanitizer products due to COVID-19, RRB is now supplying hand sanitizer manufacturers with safe, high-quality ethanol products with one of the lowest carbon footprints available on the market today. It is extremely gratifying to have a local producer supplying safe ingredients for hand sanitizers while providing local jobs to support our communities. The Red River Biorefinery serves a vital role in the region's value-added agricultural, energy, and low carbon economies," said James Leiman, Director of Economic Development and Finance Division for the State of North Dakota.

Read More

BUSINESS INSIGHTS

TriMas Closes on Acquisition of Omega

TriMas | December 21, 2021

TriMasannounced that it has closed the acquisition of Omega Plastics (“Omega”), a manufacturer of custom components and tooling for medical, as well as industrial applications, adding to TriMas’ Packaging group. Omega leverages its core injection molding capabilities, ISO Class 8 clean room and advanced in-house tool making capabilities, to provide its customers a faster product development cycle, from prototype development, testing and validation, to short and medium run production and assembly. Omega’s medical components are currently used in drug delivery, including consumable intravenous applications, as well as diagnostic testing and orthopedic applications. As of September 30, 2021, TriMas’ Packaging group’s last twelve months sales were approximately $534 million, representing approximately 64% of TriMas’ total sales. TriMas plans to expand Omega’s production capacity, as required in order to benefit its customers’ longer-term needs, while also leveraging Omega’s advanced tool making capabilities to add to TriMas Packaging’s speed-to-market advantage on innovation and new product designs. Omega is expected to generate approximately $18 million in revenue in fiscal year 2021. “We welcome Omega to TriMas’ family of businesses and look forward to working with the Omega leadership team to unleash future growth opportunities. I’d like to thank all the teams from Omega, TriMas and our respective advisors that supported the work to complete this transaction.” Thomas Amato, TriMas President & CEO The addition of Omega further expands TriMas Packaging’s Pharmaceutical & Nutraceutical product offering into supporting medical device contract development manufacturing customers.

Read More

Spotlight

The lives of pharmacists and the medicines they manage have changed dramatically since the NHS was created. Here, we chart the milestones that shaped the profession.